• Home
  •  / AstraZeneca

AstraZeneca

OverviewSuggest Edit

AstraZeneca is a global science-led biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines. It develops drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology. The company offers its products to primary care and specialty care physicians through distributors and local representative offices.

TypePublic
Founded1999
HQCambridge, GBMap
Websiteastrazeneca.com
Employee Ratings4.2More
Overall CultureC+More
View Jobs (2,151)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2020)76,100(+8%)
Job Openings2,151
Revenue (FY, 2019)$24.4 B(+11%)
Share Price (Jul 2021)£84.8
Cybersecurity ratingBMore

Key People/Management at AstraZeneca

Pascal Soriot

Pascal Soriot

Executive Director and CEO
Johan Hyllner

Johan Hyllner

Senior Director and Head of Cell Therapy, BioPharmaceuticals R&D
Marc Dunoyer

Marc Dunoyer

Executive Director and Chief Financial Officer
Katarina Ageborg

Katarina Ageborg

Executive Vice-President, Sustainability and Chief Compliance Officer; President AstraZeneca Sweden
Pam Cheng

Pam Cheng

Executive Vice-President, Operations and Information Technology
Ruud Dobber

Ruud Dobber

Executive Vice-President, BioPharmaceuticals Business Unit
Show more

AstraZeneca Office Locations

AstraZeneca has offices in Cambridge, Harlow, London, Luton and in 100 other locations
Cambridge, GB (HQ)
1 Francis Crick Ave
Cambridge, GB
136 Hills Rd
Harlow, GB
Lovet Rd
London, GB
15 Stanhope Gate
London, GB
2 Kingdom St
Luton, GB
600 Capability Green
Show all (112)

AstraZeneca Financials and Metrics

AstraZeneca Revenue

Embed Graph
View revenue for all periods
AstraZeneca's revenue was reported to be $24.38 b in FY, 2019 which is a 10.4% increase from the previous period.
USD

Revenue (Q3, 2020)

6.6b

Gross profit (Q3, 2020)

5.2b

Gross profit margin (Q3, 2020), %

79.2%

Net income (Q3, 2020)

651.0m

EBIT (Q3, 2020)

1.2b

Market capitalization (23-Jul-2021)

111.3b

Closing stock price (23-Jul-2021)

84.8

Cash (30-Sept-2020)

8.1b

EV

125.6b
AstraZeneca's current market capitalization is £111.3 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

22.5b22.1b24.4b

Revenue growth, %

(2%)(2%)10%

Cost of goods sold

4.3b4.9b4.9b

Gross profit

18.1b17.2b19.5b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

5.4b5.1b6.2b5.2b5.2b5.3b5.5b5.8b6.4b6.4b6.3b6.6b

Cost of goods sold

894.0m950.0m1.2b1.1b1.0b1.2b1.1b1.1b1.4b1.4b984.0m1.4b

Gross profit

4.5b4.1b5.0b4.0b4.1b4.2b4.4b4.8b5.1b4.9b5.3b5.2b

Gross profit Margin, %

83%81%80%78%80%78%79%82%79%78%84%79%
show all
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

3.3b4.8b5.4b

Accounts Receivable

2.8b3.0b3.6b

Inventories

3.0b2.9b3.2b

Current Assets

13.2b15.6b15.6b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

3.1b5.2b4.0b3.0b3.0b3.4b4.1b5.4b4.0b3.4b5.7b8.1b

Inventories

2.7b2.9b3.2b3.3b3.1b3.0b3.1b3.2b3.1b3.1b3.6b3.7b

Current Assets

11.6b14.3b13.6b13.2b12.4b13.1b13.6b15.2b13.5b12.8b14.9b18.2b

PP&E

7.0b7.1b7.3b7.7b7.5b7.6b7.4b7.4b7.3b7.3b7.5b7.7b
show all
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

2.9b2.1b1.2b

Depreciation and Amortization

3.0b3.8b3.8b

Inventories

(548.0m)(13.0m)(316.0m)

Accounts Payable

415.0m(103.0m)868.0m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Depreciation and Amortization

658.0m1.3b1.9b709.0m1.4b2.1b676.0m1.4b2.1b841.0m1.6b2.4b

Cash From Operating Activities

88.0m338.0m2.6b(140.0m)(75.0m)394.0m(387.0m)491.0m1.6b139.0m1.2b3.0b

Purchases of PP&E

(286.0m)(549.0m)(849.0m)(213.0m)(486.0m)(728.0m)(174.0m)(438.0m)(659.0m)(186.0m)(370.0m)(598.0m)

Cash From Investing Activities

(146.0m)(351.0m)(686.0m)273.0m177.0m36.0m328.0m(789.0m)(715.0m)9.0m157.0m(423.0m)
show all
USDQ1, 2017

Debt/Equity

1.2 x

Debt/Assets

0.3 x

Financial Leverage

4.1 x
Show all financial metrics

AstraZeneca Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Projects in R&D Pipeline

99133146132144149167171

Phase I Trials Projects

3324444150383435

Phase II Trials Projects

2711333637435042

Phase III Trials Projects

1911352723222725
Show all operating metrics

AstraZeneca Acquisitions / Subsidiaries

Company NameDateDeal Size
Alexion PharmaceuticalsDecember 12, 2020$39 b
Takeda Respiratory BusinessMay 10, 2016$575 m
AcertaPharmaDecember 17, 2015$4 b
ZS PharmaNovember 06, 2015$2.7 b
AlmirallJuly 30, 2014
Pearl TherapeuticsJune 10, 2013$1.2 b
Omthera PharmaceuticalsMay 29, 2013$323 m
Ardea BiosciencesApril 23, 2012$781 m
Guangdong BeiKang Pharmaceutical Company LtdDecember 08, 2011
NovexelDecember 23, 2009
Show more

AstraZeneca Revenue Breakdown

Embed Graph

AstraZeneca revenue breakdown by business segment: 10.7% from Other Disease Areas, 22.1% from Respiratory, Inflammation and Autoimmunity, 35.5% from Oncology, 28.3% from Cardiovascular and Metabolic Diseases and 3.4% from Other

AstraZeneca revenue breakdown by geographic segment: 17.1% from Continental Europe, 38.3% from Americas, 37.2% from Asia, Africa & Australasia and 7.5% from UK

Human Capital Metrics

Source: www.astrazeneca.com
Embed Graph
Show all human capital metrics

AstraZeneca Cybersecurity Score

Cybersecurity ratingPremium dataset

B

82/100

Learn more about our premium products
SecurityScorecard logo

AstraZeneca Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

Learn more about our premium products
CSRHub logo

AstraZeneca Online and Social Media Presence

AstraZeneca's Trends

Embed Graph

AstraZeneca Company Culture

  • Overall Culture

    C+

    68/100

  • CEO Rating

    B

    70/100

  • Compensation

    A

    78/100

  • Diversity

    B

    70/100

Learn more on Comparably

AstraZeneca News and Updates

July 22, 2021

Thinking about trading options or stock in Carnival Corp, AstraZeneca, Moderna, Las Vegas Sands, or Texas Instruments?

NEW YORK, July 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CCL, AZN, MRNA, LVS, and TXN. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...
July 22, 2021

Study says two shots of either AstraZeneca or Pfizer effective against Delta variant

Two does of the Pfizer or AstraZeneca Covid-19 vaccine provide nearly as much protection against the Delta variant as they The post Study says two shots of either AstraZeneca or Pfizer effective against Delta variant appeared first on CityAM.
July 21, 2021

Thinking about trading options or stock in Draftkings, American Airlines, Netflix, AstraZeneca, or Seagate Technology?

NEW YORK, July 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DKNG, AAL, NFLX, AZN, and STX. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...
July 20, 2021

Thinking about buying stock in Ardelyx, AstraZeneca, Rocket Companies, Teva Pharmaceutical, or JetBlue Airways?

NEW YORK, July 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARDX, AZN, RKT, TEVA, and JBLU. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
July 19, 2021

Thailand Turns to Chinese Vaccine as AstraZeneca Supply Falls Short

Thailand Turns to Chinese Vaccine as AstraZeneca Supply Falls Short
July 16, 2021

AstraZeneca says FDA advisory committee won't support CKD treatment for approval, partner FibroGen stock plunges

AstraZeneca PLC has disclosed Friday that a U.S. Food and Drug Administration advisory committee has voted 13 to 1 not to support approval of roxadustat for the treatment of anaemia in chronic kidney disease (CKD) in non-dialysis dependent adult patients. Shares of FibroGen Inc. , which was AstraZ…
Show more

AstraZeneca Blogs

July 27, 2021

AstraZeneca and Regeneron to research, develop and commercialise new small molecule medicines for obesity

July 26, 2021

Ultomiris recommended for approval in the EU by CHMP for children and adolescents with paroxysmal nocturnal haemoglobinuria

July 23, 2021

Vaxzevria is highly effective after one dose against severe disease or hospitalisation caused by Beta and Delta variants of concern

July 21, 2021

Acquisition of Alexion completed

July 19, 2021

Imfinzi approved in China for the treatment of extensive-stage small cell lung cancer

July 16, 2021

Status on FDA Advisory Committee vote on roxadustat in anaemia of chronic kidney disease

Show more

 AstraZeneca Frequently Asked Questions

  • When was AstraZeneca founded?

    AstraZeneca was founded in 1999.

  • Who are AstraZeneca key executives?

    AstraZeneca's key executives are Pascal Soriot, Johan Hyllner and Marc Dunoyer.

  • How many employees does AstraZeneca have?

    AstraZeneca has 76,100 employees.

  • What is AstraZeneca revenue?

    Latest AstraZeneca annual revenue is $24.4 b.

  • What is AstraZeneca revenue per employee?

    Latest AstraZeneca revenue per employee is $320.4 k.

  • Who are AstraZeneca competitors?

    Competitors of AstraZeneca include Daiichi Sankyo, Boehringer Ingelheim and Sanofi.

  • Where is AstraZeneca headquarters?

    AstraZeneca headquarters is located at 1 Francis Crick Ave, Cambridge.

  • Where are AstraZeneca offices?

    AstraZeneca has offices in Cambridge, Harlow, London, Luton and in 100 other locations.

  • How many offices does AstraZeneca have?

    AstraZeneca has 112 offices.